Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. (October 2022) - Reckamp, K.; Song, Z.; Gettinger, S.; Mitchell, E.P.; Wright, J.J.; Moscow, J.A.; Gray, R.J.; Wang, V.; McShane, L.M.; Rubinstein, L.V.; Patton, D.R.; Williams, P.M.; et al.